What does Splash Beverage Group do today?
Splash Beverage Group, Inc. trades on NYSE American under SBEV. Its reporting history is rooted in beverages, but its strategy is moving toward cannabinoid wellness and regulated biopharma. The company’s own corporate description now presents Splash as a platform for modern wellness brands built around cannabinoids and adjacent plant-based ingredients. That positioning differs materially from its earlier portfolio-company story.
The legacy beverage footprint
The 2025 Form 10-K identifies two reportable segments: Splash Beverage and E-commerce, historically operated through the Qplash online channel. Chispo tequila is the remaining beverage product generating reported sales, with production outsourced to contract manufacturers in Mexico. Alcohol distribution follows the three-tier system, so access to distributors, brokers, retailers, restaurants, and shelf space matters as much as brand ownership.
| Research lens | Current answer | Why it matters |
|---|---|---|
| Listing | NYSE American: SBEV | Exchange compliance and access to equity financing are central to survival. |
| Reported segments | Splash Beverage; E-commerce | The segment labels reflect the legacy model, not yet a mature wellness platform. |
| Strategic direction | Cannabinoid wellness and biopharma | Future value depends on transactions, licensing, financing, and regulatory execution. |
| Core analytical issue | Transformation under severe balance-sheet stress | Historical revenue is too small to support a conventional operating-company valuation. |
The new platform ambition
Splash’s proposed future is therefore better understood as a transaction-led reconstruction than as a simple beverage turnaround. Splash is adding licensed cannabinoid intellectual property, sector operators, investments, and potentially an established wellness business while settling legacy liabilities. The financing, operating, and regulatory pieces remain incomplete as of July 17, 2026.
How does Splash Beverage Group make money?
In the last audited year, Splash earned product revenue rather than subscription or licensing income. Beverage sales moved through distributors, while e-commerce reflected online sales and fulfillment. Neither segment covered corporate costs, and both required working capital before customers paid.
Two reporting segments, almost no current sales
Sales largely stopped after March 2025 because Splash lacked manufacturing and marketing capital. Management estimated that at least $3 million would be needed in 2026 to restart a limited tequila operation, showing how much cash must be committed before revenue can become meaningful.
How the economics could work after the pivot
The preferred outcome is a shift toward differentiated products and licensing economics, but it requires completed transactions, funding, regulatory milestones, launch execution, and repeat demand.
What does Splash Beverage Group’s latest quarter show?
The Form 10-Q for the quarter ended March 31, 2026 shows a public company with minimal operating revenue and a loss structure dominated by overhead and financing costs. The $4,224 of quarterly revenue came from Chispo tequila sold to Señor Frog’s. That amount was 93.8% below the $68,606 reported in the first quarter of 2025.
Q1 2026 snapshot
| Metric | Q1 2026 | Q1 2025 | Interpretation |
|---|---|---|---|
| Revenue | $4,224 | $68,606 | Current operating activity is immaterial relative to public-company costs. |
| Gross profit | $1,848 | $28,559 | Positive unit gross profit exists, but the revenue base is too small to matter. |
| Operating expenses | $980,818 | $1,683,847 | Costs fell 41.7%, yet remained more than 230 times quarterly revenue. |
| Interest expense | $889,455 | $1,231,788 | Financing cost alone was more than 210 times Q1 2026 revenue. |
| Net loss | $(2,136,469) | $(3,650,492) | The loss narrowed, but not because a scaled operating business emerged. |
Why the loss structure matters
Operating loss is only part of the problem. Write-offs and debt-discount amortization further widened the loss. A turnaround must establish meaningful revenue while simplifying liabilities and the capital structure.
Why did the original beverage strategy break down?
Splash assembled alcoholic and non-alcoholic beverage brands, but small brands require sustained inventory, distribution, retail, and marketing investment. The company never achieved the scale or capital base needed; its 2025 annual report says beverage operations were historically unprofitable and sales stopped after March 2025 for lack of capital.
Turning points that still shape the thesis
-
2020Splash reached the public markets and acquired Copa di Vino, adding assets and obligations that were later discontinued.
-
2021The stock began trading on NYSE American, adding public-capital access and recurring compliance costs.
-
2024The TapouT license ended and litigation continued, illustrating the risk of underfunded licensed brands.
-
March 2025A 1-for-40 reverse split became effective; sales then largely stopped as liquidity blocked normal production and marketing.
-
2025Copa di Vino stayed discontinued, while a Costa Rica water-asset transaction was cancelled after seller nonperformance.
-
March 2026Splash signed a nonbinding Medterra letter of intent, formalizing the wellness pivot and its financing need.
-
June–July 2026Management added sector leadership, invested in Avicanna, licensed CannEpil, negotiated debt settlements, and pursued NYSE compliance.
The history shows Splash pursuing strategic change through acquisitions, licenses, preferred securities, convertibles, and equity before the prior model became self-funding. The wellness strategy must therefore be judged on completed transactions, cash needs, dilution, and commercialization milestones—not announcement volume.
The cannabinoid pivot changes the competitive set
The pivot places Splash in two different markets. Consumer wellness depends on brands, channels, compliance, and repeat purchase; regulated medicine depends on clinical evidence, manufacturing quality, intellectual property, approval, and physician adoption.
CannEpil creates a biopharma option
On July 6, 2026, Splash disclosed an exclusive worldwide license for CannEpil, an oral CBD/THC formulation intended for drug-resistant or refractory epilepsy and seizure disorders. The agreement includes a 15% net-revenue royalty, development milestones, Series D preferred consideration valued at $5.5 million, and at least $1 million of related commercialization support.
The regulatory hurdle is substantial. The FDA’s cannabis and CBD guidance notes that Epidiolex is already approved for specific seizure disorders. CannEpil must establish safety, efficacy, quality, and a differentiated clinical role.
Competition now spans brands and regulated medicine
| Arena | Competitive pressure | Splash’s current position | Critical differentiator |
|---|---|---|---|
| Tequila | Global spirits portfolios, regional producers, retailer shelf-space competition | Chispo has minimal reported sales and limited marketing capital | Distributor commitment and repeat sell-through |
| Consumer wellness | Established CBD brands, private labels, changing channel policies | Platform is being assembled through proposed transactions and investments | Compliance, formulation credibility, and efficient customer acquisition |
| Cannabinoid biopharma | Approved therapies and development-stage neurological programs | CannEpil is an option-stage licensed asset, not a commercial product | Clinical data, regulatory approval, patents, and reimbursement |
| Capital markets | Other micro-cap issuers competing for risk capital | Going-concern uncertainty and heavy dilution increase financing friction | Credible milestones and disciplined use of proceeds |
Splash also made a minority investment in Avicanna in June 2026, according to an official transaction filing. The investment may provide sector exposure, but it does not substitute for a funded platform or validated clinical program.
How financially strong is Splash Beverage Group?
Financially, Splash is distressed. At March 31, 2026, current assets were $708,848 against $16.97 million of current liabilities, and stockholders’ deficit was $16.20 million. Management said available capital was insufficient for the following 12 months, leaving the company dependent on external financing.
Liquidity is financing-dependent
Q1 2026 operating cash use was approximately $0.9 million. An equity line supplied $1.37 million through 3.17 million newly issued shares. This was financing liquidity, not internally generated cash.
Capital structure matters more than book debt alone
| Capital item | Official figure | Period | Analytical implication |
|---|---|---|---|
| Common shares outstanding | 10.96M | May 18, 2026 | The denominator had already expanded sharply from year-end 2025. |
| Convertible-note share exposure | 8.39M shares | March 31, 2026 | Potential conversion can transfer more economics to financing counterparties. |
| Equity-incentive plan reserve | 5.32M shares | March 31, 2026 | Compensation capacity is large relative to the then-current share base. |
| Planned reverse split | 1-for-4 | Scheduled after July 24, 2026 market close | The split changes quoted share count and price, not economic dilution. |
A July 14 company announcement said negotiated settlements covered approximately $3.3 million of legacy liabilities for roughly $550,000 in cash, subject to final accounting and payment. This is meaningful liability relief if completed, but it consumes scarce cash and does not create operating revenue.
Who owns and controls Splash Beverage Group?
Splash has ordinary common voting rights, but ownership changes rapidly as equity, preferred conversions, debt, and options expand the denominator. The latest detailed beneficial-ownership table in the 2025 proxy statement used a 2.14 million-share record-date denominator, so its percentages are not current after later issuances.
A stale ownership snapshot in a rapidly changing denominator
| Holder or group | Shares | Proxy ownership | Why it matters |
|---|---|---|---|
| Justin Yorke and affiliated funds | 137,155 | 6.40% | Largest identified beneficial holder in the proxy snapshot. |
| Directors and executive officers as a group | 173,908 | 8.11% | Insider alignment existed, but subsequent issuance reduces the percentage unless insiders add shares. |
| Robert Nistico | 36,753 | 1.71% | Founder-era influence was economically modest by the proxy record date. |
| LK Family Partnership | 74,800 | 3.49% | Another meaningful holder in the historical ownership table. |
By May 18, 2026, common shares had risen to 10.96 million; the July reverse-split announcement later referenced about 25.2 million pre-split shares. Governance therefore turns on new security recipients, conversion rights, and financing-counterparty influence.
Incentives and governance
Brady Cobb became interim chief executive in May 2026, and Michael Bondurant was later appointed chief operating officer. Their arrangements include salary, options, and market-capitalization-based bonuses. Researchers should distinguish value created by durable operating progress from gains driven by financing, announcements, or share-structure changes.
What opportunities could rebuild the company?
The opportunity is to replace an undercapitalized beverage portfolio with differentiated assets and better margin potential. Three pathways matter: a transformative acquisition, licensed intellectual-property commercialization, and legacy-debt reduction.
Transaction-led scale is the fastest route
The original Medterra letter of intent is strategically understandable: an established wellness platform could supply revenue, products, channels, and operating infrastructure more quickly than internal development. However, definitive documentation, audited target financials, financing, shareholder approvals, and closing conditions remain essential. Until those steps occur, the transaction belongs in a probability-weighted scenario rather than the base case.
The NYSE American accepted Splash’s compliance plan and gave the company until January 29, 2027 to regain the required shareholders’ equity standard, according to a July 2026 filing. That creates time, not certainty. The best outcome is a sequence in which debt relief, financing, and new operations reinforce one another.
What risks could change Splash Beverage Group’s outcome?
Splash’s risks reinforce one another: financing constraints can stop operations, weak revenue worsens creditor and listing pressure, and those pressures can force dilutive funding. Regulatory and transaction risks sit on top of that cycle.
| Risk | Evidence | Financial transmission | What to monitor |
|---|---|---|---|
| Going concern and liquidity | Cash of $381,195 versus $16.97M of liabilities at March 31, 2026 | Operations and transactions can halt without continuous funding. | Cash balance, operating burn, financing proceeds, overdue obligations |
| Dilution | Rapid share issuance plus notes, preferred stock, warrants, and options | Enterprise progress may not translate proportionally to each common share. | Fully diluted shares and effective issue price |
| Transaction failure | Medterra arrangement is nonbinding and financing-dependent | Expected scale, revenue, and strategic credibility may not arrive. | Definitive agreement, audited financials, approvals, closing funding |
| Clinical and regulatory execution | CannEpil requires trials, regulatory filings, and timely approvals | Development spending may produce no commercial product. | Trial initiation, enrollment, data, FDA interactions, milestone compliance |
| Listing compliance | Equity-standard cure period ends January 29, 2027 | Delisting could reduce liquidity and financing access. | NYSE updates, equity balance, bid-price and reporting compliance |
| Legacy claims and obligations | Past-due creditors, litigation, discontinued-operation liabilities | Cash settlements and legal costs compete with growth investment. | Settlement completion, releases, remaining claims, covenant terms |
What should researchers monitor next?
- Revenue quality: whether new revenue comes from recurring commercial demand rather than isolated legacy beverage sales.
- Gross profit dollars: absolute gross profit must rise far faster than percentage margins.
- Cash burn: compare quarterly operating cash use with unrestricted cash and committed financing.
- Fully diluted shares: incorporate preferred conversions, notes, warrants, options, and acquisition consideration.
- Debt settlement execution: confirm payments, releases, and accounting gains rather than relying on announcements.
- Clinical milestones: track funded trial activity and regulatory evidence for CannEpil.
- Listing status: monitor the January 2027 equity-compliance deadline and other continued-listing standards.
The scheduled 1-for-4 reverse split may help market mechanics, but it cannot repair negative equity or create cash flow. A debt-extinguishment gain helps reported equity only if settlements close and does not create a sustainable business.
What is the key takeaway for a DCF analysis?
Splash is not suited to a single-scenario DCF built from recent revenue. The operating base is negligible, while value depends on conditional events: acquisitions, financing, settlements, clinical development, approval, launch, and exchange compliance.
A probability-weighted framework is more defensible
| Valuation driver | Base-case treatment | Upside requirement | Downside signal |
|---|---|---|---|
| Legacy operations | Use minimal revenue and continued overhead until evidence changes | Repeat sales, positive gross profit, disciplined working capital | Further write-offs or permanent discontinuation |
| Medterra | Exclude from consolidated cash flow until a definitive, financed closing | Audited target results and financing that leaves value for common holders | LOI expiry, funding failure, or punitive consideration |
| CannEpil | Treat as risk-adjusted option value, not commercial revenue | Funded trials, credible data, regulatory progress, protected economics | Missed milestones, termination, or inability to fund development |
| Capital structure | Model debt, preferred claims, royalties, and fully diluted shares explicitly | Debt relief and financing at progressively better terms | Continued low-price issuance and expanding conversion exposure |
| Terminal value | Use no mature-growth assumption until a durable business exists | Stable revenue, gross margin, reinvestment needs, and positive free cash flow | Going-concern persistence or loss of listing access |
A practical model separates the legacy entity from transaction options, probability-weights milestones, forecasts financing needs, and divides residual equity value by a fully diluted share count. The discount rate should reflect micro-cap liquidity, execution, regulation, and distress. Reverse splits and accounting gains are not operating value creation.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.